Filing Flows › Comparisons › NEPH vs VVOS
Nephros vs Vivos Therapeutics: NEPH and VVOS compared
Nephros is the larger company: $5.6M of revenue in its latest quarter (Q3 2026) against $5.2M for Vivos Therapeutics (Q2 2026). Vivos Therapeutics is growing faster (+35% against +18% a year earlier). Nephros is more profitable, with an operating margin of 8.9% against -93.6%.
Where the money goes: NEPH and VVOS
Nephros (NEPH) · Q3 2026
Nephros, Q3 2026: revenue $5.6M (+18% year over year), operating margin 8.9%, net earnings $512K, operating cash flow −$150K. The chart follows the revenue to costs, profit and cash.
Vivos Therapeutics (VVOS) · Q2 2026
Vivos Therapeutics, Q2 2026: revenue $5.2M (+35% year over year), operating margin -93.6%, net loss $5.5M, operating cash flow −$3.1M. The chart follows the revenue to costs, profit and cash.
| Nephros (NEPH) | Vivos Therapeutics (VVOS) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 2026 |
| Revenue | $5.6M | $5.2M |
| Revenue growth, Y/Y | +18% | +35% |
| Gross margin | 58.4% | — |
| Operating margin | 8.9% | -93.6% |
| Net earnings | $512K | −$5.5M |
| Net margin | 9.1% | -107.2% |
| Operating cash flow | −$150K | −$3.1M |
Where the revenue comes from
Nephros
- Product: $5.4M (97%)
- Service Royalty and Other Revenues: $191K (3%)
Vivos Therapeutics
- Service: $3.8M (74%)
- Product: $1.4M (26%)
Questions
Which is bigger, Nephros or Vivos Therapeutics?
Nephros is the larger company: $5.6M of revenue in its latest quarter (Q3 2026) against $5.2M for Vivos Therapeutics (Q2 2026).
Is Nephros or Vivos Therapeutics growing faster?
Vivos Therapeutics is growing faster (+35% against +18% a year earlier).
Which is more profitable, Nephros or Vivos Therapeutics?
Nephros is more profitable, with an operating margin of 8.9% against -93.6%.
More: Nephros earnings · how Nephros makes money · Vivos Therapeutics earnings · how Vivos Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Aug 14, 2026). Fiscal quarters can end on different dates. Not investment advice.